Valvular heart disease and the use of cabergoline for the treatment of prolactinoma

Clinical Endocrinology

Volumn 70, Issue 1, 2009, Pages 104-108

  Herring, Neil ^a,b   Szmigielski, Cezary ^b   Becher, Harald ^b   Karavitaki, Niki ^c   Wass, John A H ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART VALVE REGURGITATION; HUMAN; MALE; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; SEX DIFFERENCE; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE;

AORTIC VALVE INSUFFICIENCY; CALCINOSIS; ECHOCARDIOGRAPHY; ERGOLINES; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; PROLACTINOMA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 58149161395     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03458.x     Document Type: Article

References (18)

1. Horvath, J., Fross, R.D., Kleiner-Fisman, G., Lerch, R., Stalder, H., Liaudat, S., Raskoff, W.J., Flachsbart, K.D., Rakowski, H., Pache, J.C., Burkhard, P.R. Lang, A.E. (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Movement Disorders, 19, 656 662.
2. Pinero, A., Marcos-Alberca, P. Fortes, J. (2005) Cabergoline-related severe restrictive mitral regurgitation. New England Journal of Medicine, 353, 1976 1977.
3. Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. Garbe, E. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 356, 29 38.
4. Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S. Pezzoli, G. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine, 356, 39 46.
5. Rothman, R.B., Baumann, M.H., Savage, J.E., Rauser, L., McBride, A., Hufeisen, S.J. Roth, B.L. (2000) Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 102, 2836 2841.
6. Newman-Tancredi, A., Cussac, D., Quentric, Y., Touzard, M., Verrièle, L., Carpentier, N. Millan, M.J. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. Journal of Pharmacology and Experimental Therapeutics, 303, 815 822.
7. Redfield, M.M., Nicholson, W.J., Edwards, W.D. Tajik, A.J. (1992) Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Annals of Internal Medicine, 117, 50 52.
8. Leeson, P., Mitchell, A. Becher, H. (eds) (2007) Oxford Specialist Handbooks in Cardiology: Echocardiography. Oxford University Press, Oxford.
9. Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C. Schoors, D. (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet, 363, 1179 1183.
10. Lancellotti, P., Lebrun, F. Pierard, L.A. (2003) Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction. Journal of the American College of Cardiology, 42, 1921 1928.
11. Srichai, M.B., Grimm, R.A., Stillman, A.E., Gillinov, A.M., Rodriguez, L.L., Lieber, M.L., Lara, A., Weaver, J.A., McCarthy, P.M. White, R.D. (2005) Ischaemic mitral regurgitation: impact of the left ventricle and mitral valve in patients with left ventricular systolic dysfunction. Annals of Thoracic Surgery, 80, 170 178.
12. Wakil, A., Rigby, A., Clark, A. Atkin, S. (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology, 159, R11 R14.
13. Lancellotti, P., Livadariu, E., Markov, M., Daly, A., Burlacu, M.C., Betea, D., Pierard, L. Beckers, A. (2008) Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology, 159, 1 5.
14. Kars, M., Delgado, V., Holman, E.R., Feelders, R.A., Smit, J.W., Romijn, J.A., Bax, J.J. Pereira, A.M. (2008) Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. Journal of Clinical Endocrinology and Metabolism, 93, 3348 3356.
15. Bogazzi, F., Buralli, S., Manetti, L., Raffaelli, V., Cigni, T., Lombardi, M., Boresi, F., Taddei, S., Salvetti, A. Martino, E. (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice. doi:.
16. Vallette, S., Serri, K., Rivera, J., Santagata, P., Delorme, S., Garfield, N., Kahtani, N., Beauregard, H., Aris-Jilwan, N., Houde, G. Serri, O. (2008) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. doi:.
17. Colao, A., Galderisi, M., Di Sarno, A., Pardo, M., Gaccione, M., D'Andrea, M., Guerra, E., Pivonello, R., Lerro, G. Lombardi, G. (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. Journal of Clinical Endocrinology and Metabolism, 93, 3777 3784.
18. Colao A. (2008) The GH-IGF-I axis and the cardiovascular system: clinical implications. Clinical Endocrinology, 69, 347 358.